Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
PaperCitations, authors & open-access status
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 40 citations, 2022 year and bronze oa status.
40
Citations
2022
Year
bronze
OA Status